What are the effects of radioisotopes in people with metastatic bone pain?

2017 ◽  
Author(s):  
Christopher Bunt
Keyword(s):  
Bone Pain ◽  
Metastatic Bone Pain

Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients

2001 ◽  
Vol 66 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Rosa Sciuto ◽  
Anna Festa ◽  
Rosella Pasqualoni ◽  
Alessandro Semprebene ◽  
Sandra Rea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Pain ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain

scholarly journals Sex-difference affects disease progression in the MRMT-1 model of cancer-induced bone pain

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 445
Author(s):  
Sarah Falk ◽  
Tamara Al-Dihaissy ◽  
Laura Mezzanotte ◽  
Anne-Marie Heegaard
Keyword(s):  
Mammary Cancer ◽  
Bone Pain ◽  
Pain Processing ◽  
Mammary Cells ◽  
In Vivo Models ◽  
Metastatic Bone Pain ◽  
Essential Parameter ◽  
Pain State ◽  
Males And Females

An overwhelming amount of evidence demonstrates sex-induced variation in pain processing, and has thus increased the focus on sex as an essential parameter for optimization of in vivo models in pain research. Mammary cancer cells are often used to model metastatic bone pain in vivo, and are commonly used in both males and females. Here we demonstrate that compared to males, females have an increased capacity for recovery following inoculation of MRMT-1 mammary cells, thus potentially causing a sex-dependent bias of the progression of the pain state.

Effects of massage on pain, mood status, relaxation, and sleep in Taiwanese patients with metastatic bone pain: A randomized clinical trial

Pain ◽  
2011 ◽  
Vol 152 (10) ◽  
pp. 2432-2442 ◽  
Author(s):  
Sui-Whi Jane ◽  
Shu-Ling Chen ◽  
Diana J. Wilkie ◽  
Yung-Chang Lin ◽  
Shuyuann Wang Foreman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Bone Pain ◽  
Metastatic Bone Pain

scholarly journals Radioisotopes for metastatic bone pain

2017 ◽  
Author(s):  
Marta Roqué i Figuls ◽  
Maria José Martinez-Zapata ◽  
Martin Scott-Brown ◽  
Pablo Alonso-Coello
Keyword(s):  
Bone Pain ◽  
Metastatic Bone Pain

Metastatic Bone Pain Management

2018 ◽  
pp. 281-281
Author(s):  
Raghbir Gehdoo ◽  
Jasmeen Kaur
Keyword(s):  
Pain Management ◽  
Bone Pain ◽  
Metastatic Bone Pain

Denosumab-induced hypocalcaemia in metastatic gastric cancer

2020 ◽  
pp. bmjspcare-2020-002548
Author(s):  
Craig Gouldthorpe ◽  
Richard Quinton ◽  
Donna Wakefield
Keyword(s):  
Gastric Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Bone Pain ◽  
Metastatic Gastric Cancer ◽  
Metastatic Bone Pain ◽  
Electrolyte Replacement ◽  
Intravenous Calcium

Hypocalcaemia in malignancy is infrequently reported and the underlying cause is often multifactorial. Denosumab, an antiresorptive medication, can be used to treat a number of cancer-related complications including hypercalcaemia, metastatic bone pain and to reduce fracture-events. We present a case of a hospice inpatient with profound and recurring hypocalcaemia following a single denosumab infusion which required repeated hospitalisation, for intravenous calcium, alongside a prolonged course of vitamin D and electrolyte replacement. The case highlights the risk of hypocalcaemia with denosumab use, together with the need to identify and treat vitamin D deficiency in both the prevention and management of such a complication.

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

1998 ◽  
Vol 16 (12) ◽  
pp. 3890-3899 ◽  
Author(s):  
J J Body ◽  
R Bartl ◽  
P Burckhardt ◽  
P D Delmas ◽  
I J Diel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multiple Myeloma ◽  
Cancer Patients ◽  
Bone Pain ◽  
Objective Response ◽  
Metastatic Breast ◽  
Morbidity Rate ◽  
Duration Of Treatment ◽  
Analgesic Effects ◽  
Metastatic Bone Pain

PURPOSE The purpose of this article is to review the recent data on bisphosphonate use in oncology and to provide some guidelines on the indications for their use in cancer patients. DESIGN The group consensus reached by experts on the rationale for the use of bisphosphonates in cancer patients and their current indications for the treatment of tumor-induced hypercalcemia and metastatic bone pain in advanced disease and for the prevention of the complications of multiple myeloma and of metastatic bone disease are reviewed. RESULTS Bisphosphonates are potent inhibitors of tumor-induced osteoclast-mediated bone resorption. They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect. Intravenous bisphosphonates exert clinically relevant analgesic effects in patients with metastatic bone pain. Regular pamidronate infusions can also achieve a partial objective response by conventional International Union Against Cancer criteria and enhance the objective response rate to chemotherapy. In breast cancer, the prolonged administration of oral clodronate 1,600 mg daily reduces the frequency of morbid skeletal events by more than one fourth, whereas monthly pamidronate infusions of 90 mg for only 1 year in addition to chemotherapy reduce by more than one third the frequency of all skeletal-related events. The use of bisphosphonates to prevent bone metastases remains experimental. Last, bisphosphonates in addition to chemotherapy are superior to chemotherapy alone in patients with stages II and III multiple myeloma and can reduce the skeletal morbidity rate by approximately one half. CONCLUSION Bisphosphonate use is a major therapeutic advance in the management of the skeletal morbidity caused by metastatic breast cancer or multiple myeloma, although many questions remain unanswered, notably regarding the optimal selection of patients and the duration of treatment.

Sign in / Sign up

Export Citation Format

Share Document